{"id":748526,"date":"2023-04-18T08:19:25","date_gmt":"2023-04-18T12:19:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/"},"modified":"2023-04-18T08:19:25","modified_gmt":"2023-04-18T12:19:25","slug":"acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/","title":{"rendered":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., April  18, 2023  (GLOBE NEWSWIRE) &#8212; Acrivon Therapeutics, Inc. (\u201cAcrivon\u201d or \u201cAcrivon Therapeutics\u201d) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company\u2019s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually.<\/p>\n<p align=\"justify\">To access the live webcast of this fireside chat, visit the Events &amp; Presentations page within the investor section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4XqUkbXIpaLJ52ElH4nRTPnZdgZEaotfBpmybY7I3Z2pHuibxgXV4_yH_RNQT8UbjyUgzlAs30_fGdcIdiMGZ_wixoDdyFUmS8ctY08NR6sKNHhyC7bcjoo0nnR5zlkzxhwjmKQtYEI1O_tc1eTk3OCRuC5CRFa0ZernD_p52ZPxK0y8W9ZEhF8EqbaeJIyP\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.acrivon.com\/news-events\/events-presentations<\/a>. A replay of the webcast will be available via the same link for 90 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About Acrivon Therapeutics<\/strong><br \/>\n        <br \/>Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon\u2019s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature<sup>\u00ae<\/sup> companion diagnostics that are used to identify the patients most likely to benefit from Acrivon\u2019s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. Acrivon\u2019s ACR-368 OncoSignature<sup>\u00ae<\/sup> test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs targeting two critical nodes in the DNA Damage Response, or DDR, including WEE1, a protein serine\/threonine kinase, and the closely related PKMYT1.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release includes certain disclosures that contain \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled \u201cRisk Factors\u201d in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong><br \/>\n        <br \/>Alexandra Santos<br \/>asantos@wheelhouselsa.com<\/p>\n<p>Aljanae Reynolds<br \/>areynolds@wheelhouselsa.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDk3NGU0MjUtNmFiYS00NTEzLWIxMTItMDZmOTE3Mzg5NTg2LTEyMjIxMzk=\/tiny\/Acrivon-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) &#8212; Acrivon Therapeutics, Inc. (\u201cAcrivon\u201d or \u201cAcrivon Therapeutics\u201d) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company\u2019s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually. To access the live webcast of this fireside chat, visit the Events &amp; Presentations page within the investor section of the company\u2019s website at https:\/\/ir.acrivon.com\/news-events\/events-presentations. A replay of the webcast &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748526","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) &#8212; Acrivon Therapeutics, Inc. (\u201cAcrivon\u201d or \u201cAcrivon Therapeutics\u201d) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company\u2019s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually. To access the live webcast of this fireside chat, visit the Events &amp; Presentations page within the investor section of the company\u2019s website at https:\/\/ir.acrivon.com\/news-events\/events-presentations. A replay of the webcast &hellip; Continue reading &quot;Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T12:19:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference\",\"datePublished\":\"2023-04-18T12:19:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/\"},\"wordCount\":555,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/\",\"name\":\"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\",\"datePublished\":\"2023-04-18T12:19:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/","og_locale":"en_US","og_type":"article","og_title":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) &#8212; Acrivon Therapeutics, Inc. (\u201cAcrivon\u201d or \u201cAcrivon Therapeutics\u201d) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company\u2019s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually. To access the live webcast of this fireside chat, visit the Events &amp; Presentations page within the investor section of the company\u2019s website at https:\/\/ir.acrivon.com\/news-events\/events-presentations. A replay of the webcast &hellip; Continue reading \"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-18T12:19:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference","datePublished":"2023-04-18T12:19:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/"},"wordCount":555,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/","name":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=","datePublished":"2023-04-18T12:19:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODQ2MyM1NTI3OTY0IzIyMTA1ODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acrivon-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748526"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748526\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}